Keywords
Last Name
Institution

Eric G. Meissner

Title
InstitutionMedical University of South Carolina
DepartmentInfectious Diseases
AddressP.O. Box MSC 752
Rutledge Tower Building - 135 Rutledge Ave.
Phone843-792-4541
Fax843-792-6680
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Innate immunity
    Hepatitis C virus (HCV)
    Human immunodeficiency virus (HIV)
    Interferon lambda (IFNL3, IFNL4)
    Lipid metabolism
    mRNA and miRNA transcriptional profiling
    Collapse keywords
    Digestive System, HIV / AIDS, Infectious Diseases, Immune System, Liver

    Collapse ORNG Applications 
    Collapse studies/trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Muiruri C, Longenecker CT, Meissner EG, Okeke NL, Pettit AC, Thomas K, Velazquez E, Bloomfield GS. Prevention of cardiovascular disease for historically marginalized racial and ethnic groups living with HIV: A narrative review of the literature. Prog Cardiovasc Dis. 2020 Feb 11. PMID: 32057785.
      View in: PubMed
    2. Gedney R, Butler Willis K, O'Brien A, Luciano M, Richardson KJ, Meissner EG. Identification of Priority Areas for Increased Testing Using Geospatial Mapping of Incident HIV Cases Near Charleston, South Carolina. Infect Dis (Auckl). 2019; 12:1178633719870759. PMID: 31467478.
      View in: PubMed
    3. Lazenby GB, Orr C, Guille C, Meissner EG. Increasing Prevalence of Chronic Hepatitis C Virus Infection in a Southern Academic Obstetrical Clinic. South Med J. 2019 06; 112(6):325-330. PMID: 31158887.
      View in: PubMed
    4. Orr C, Aartun J, Masur H, Kottilil S, Meissner EG. Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin. J Viral Hepat. 2019 03; 26(3):323-328. PMID: 30383918.
      View in: PubMed
    5. Meissner EG. The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression? Clin Infect Dis. 2018 08 31; 67(6):878-880. PMID: 29718134.
      View in: PubMed
    6. Tolson C, Richey LE, Zhao Y, Korte JE, Brady K, Haynes L, Meissner EG. Association of Substance Use With Hospitalization and Virologic Suppression in a Southern Academic HIV Clinic. Am J Med Sci. 2018 06; 355(6):553-558. PMID: 29891038.
      View in: PubMed
    7. Obajemu AA, Rao N, Dilley KA, Vargas JM, Sheikh F, Donnelly RP, Shabman RS, Meissner EG, Prokunina-Olsson L, Onabajo OO. IFN-?4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling. J Immunol. 2017 12 01; 199(11):3808-3820. PMID: 29070670.
      View in: PubMed
    8. Meissner EG, McGillicuddy JW, Squires J, Skipper D, Self S, Wray D, Moritz ED, Stramer SL, Nadig S. Across state lines: Fulminant Babesia microti infection in a liver transplant recipient. Transpl Infect Dis. 2017 Oct; 19(5). PMID: 28644910.
      View in: PubMed
    9. Meissner EG, Kohli A, Higgins J, Lee YJ, Prokunina O, Wu D, Orr C, Masur H, Kottilil S. Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection. Hepatol Commun. 2017 Sep; 1(7):586-594. PMID: 29202115.
      View in: PubMed
    10. Luo Z, Li Z, Martin L, Wan Z, Meissner EG, Espinosa E, Wu H, Yu X, Fu P, Julia Westerink MA, Kilby JM, Wu J, Huang L, Heath SL, Li Z, Jiang W. Pathological Role of Anti-CD4 Antibodies in HIV-Infected Immunologic Nonresponders Receiving Virus-Suppressive Antiretroviral Therapy. J Infect Dis. 2017 07 01; 216(1):82-91. PMID: 28498953.
      View in: PubMed
    11. Goyal A, Lurie Y, Meissner EG, Major M, Sansone N, Uprichard SL, Cotler SJ, Dahari H. Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. Antiviral Res. 2017 08; 144:281-285. PMID: 28673800.
      View in: PubMed
    12. Meissner EG. Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era. Curr Opin Gastroenterol. 2017 May; 33(3):120-127. PMID: 28234770.
      View in: PubMed
    13. Gharib AM, Han MAT, Meissner EG, Kleiner DE, Zhao X, McLaughlin M, Matthews L, Rizvi B, Abd-Elmoniem KZ, Sinkus R, Levy E, Koh C, Myers RP, Subramanian GM, Kottilil S, Heller T, Kovacs JA, Morse CG. Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease. Biomed Res Int. 2017; 2017:2067479. PMID: 28480218.
      View in: PubMed
    14. Jimmerson LC, Clayton CW, MaWhinney S, Meissner EG, Sims Z, Kottilil S, Kiser JJ. Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines. Antiviral Res. 2017 02; 138:79-85. PMID: 27956135.
      View in: PubMed
    15. Eckard AR, Meissner EG, Singh I, McComsey GA. Cardiovascular Disease, Statins, and HIV. J Infect Dis. 2016 Oct 01; 214 Suppl 2:S83-92. PMID: 27625435.
      View in: PubMed
    16. Jimmerson LC, Urban TJ, Truesdale A, Baouchi-Mokrane F, Kottilil S, Meissner EG, Sims Z, Langness JA, Hodara A, Aquilante CL, Kiser JJ. Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels. J Clin Pharmacol. 2017 01; 57(1):118-124. PMID: 27349952.
      View in: PubMed
    17. Meissner EG, McLaughlin M, Matthews L, Gharib AM, Wood BJ, Levy E, Sinkus R, Virtaneva K, Sturdevant D, Martens C, Porcella SF, Goodman ZD, Kanwar B, Myers RP, Subramanian M, Hadigan C, Masur H, Kleiner DE, Heller T, Kottilil S, Kovacs JA, Morse CG. Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial. Liver Int. 2016 12; 36(12):1783-1792. PMID: 27232579.
      View in: PubMed
    18. Bean M, Tang L, Kottilil S, Beavers KL, Meissner EG. On-Treatment Elevation in Hepatic Transaminases during HCV Treatment with Ombitasvir, Paritaprevir, Dasabuvir, Ritonavir, and Ribavirin: A Case Series. Case Rep Infect Dis. 2016; 2016:6151570. PMID: 27313921.
      View in: PubMed
    19. Shrivastava S, Meissner EG, Funk E, Poonia S, Shokeen V, Thakur A, Poonia B, Sarin SK, Trehanpati N, Kottilil S. Elevated hepatic lipid and interferon stimulated gene expression in HCV GT3 patients relative to non-alcoholic steatohepatitis. Hepatol Int. 2016 Nov; 10(6):937-946. PMID: 27193023.
      View in: PubMed
    20. Meissner EG, Kohli A, Virtaneva K, Sturdevant D, Martens C, Porcella SF, McHutchison JG, Masur H, Kottilil S. Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. J Viral Hepat. 2016 07; 23(7):496-505. PMID: 26840694.
      View in: PubMed
    21. Luo Z, Ma L, Zhang L, Martin L, Wan Z, Warth S, Kilby A, Gao Y, Bhargava P, Li Z, Wu H, Meissner EG, Li Z, Kilby JM, Liao G, Jiang W. Key differences in B cell activation patterns and immune correlates among treated HIV-infected patients versus healthy controls following influenza vaccination. Vaccine. 2016 Apr 07; 34(16):1945-55. PMID: 26721328.
      View in: PubMed
    22. Townsend K, Meissner EG, Sidharthan S, Sampson M, Remaley AT, Tang L, Kohli A, Osinusi A, Masur H, Kottilil S. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. AIDS Res Hum Retroviruses. 2016 May; 32(5):456-62. PMID: 26559180.
      View in: PubMed
    23. Kohli A, Kattakuzhy S, Sidharthan S, Nelson A, McLaughlin M, Seamon C, Wilson E, Meissner EG, Sims Z, Silk R, Gross C, Akoth E, Tang L, Price A, Jolley TA, Emmanuel B, Proschan M, Teferi G, Chavez J, Abbott S, Osinusi A, Mo H, Polis MA, Masur H, Kottilil S. Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial. Ann Intern Med. 2015 Dec 15; 163(12):899-907. PMID: 26595450.
      View in: PubMed
    24. Meissner EG, Decalf J, Casrouge A, Masur H, Kottilil S, Albert ML, Duffy D. Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy. PLoS One. 2015; 10(7):e0133236. PMID: 26181438.
      View in: PubMed
    25. Rower JE, Meissner EG, Jimmerson LC, Osinusi A, Sims Z, Petersen T, Bushman LR, Wolfe P, McHutchison JG, Kottilil S, Kiser JJ. Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. J Antimicrob Chemother. 2015 Aug; 70(8):2322-9. PMID: 25971261.
      View in: PubMed
    26. Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, Bon D, Silk R, Gross C, Price A, Sajadi M, Sidharthan S, Sims Z, Herrmann E, Hogan J, Teferi G, Talwani R, Proschan M, Jenkins V, Kleiner DE, Wood BJ, Subramanian GM, Pang PS, McHutchison JG, Polis MA, Fauci AS, Masur H, Kottilil S. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015 Mar 24-31; 313(12):1232-9. PMID: 25706232.
      View in: PubMed
    27. Meissner EG. Continued value in understanding viral kinetic decline during interferon-free therapy for HCV. Liver Int. 2015 Feb; 35(2):295-6. PMID: 25424883.
      View in: PubMed
    28. Meissner EG, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, McHutchison J, Subramanian M, Sampson M, Naggie S, Patel K, Remaley AT, Masur H, Kottilil S. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology. 2015 Mar; 61(3):790-801. PMID: 25203718.
      View in: PubMed
    29. Kohli A, Funk E, Burbelo P, Barrett L, Meissner EG, Santich B, Shaffer A, Johl J, Sidharthan S, Moir S, Kottilil S, Fauci AS. Persistently elevated abnormal B-cell subpopulations and anti-core antibodies in patients co-infected with HIV/HCV who relapse. J Med Virol. 2015 Apr; 87(4):544-52. PMID: 25611329.
      View in: PubMed
    30. Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, Bon D, Marti MM, Silk R, Kotb C, Gross C, Jolley TA, Sidharthan S, Petersen T, Townsend K, Egerson D, Kapoor R, Spurlin E, Sneller M, Proschan M, Herrmann E, Kwan R, Teferi G, Talwani R, Diaz G, Kleiner DE, Wood BJ, Chavez J, Abbott S, Symonds WT, Subramanian GM, Pang PS, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet. 2015 Mar 21; 385(9973):1107-13. PMID: 25591505.
      View in: PubMed
    31. Osinusi A, Kohli A, Marti MM, Nelson A, Zhang X, Meissner EG, Silk R, Townsend K, Pang PS, Subramanian GM, McHutchison JG, Fauci AS, Masur H, Kottilil S. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med. 2014 Nov 04; 161(9):634-8. PMID: 25364884.
      View in: PubMed
    32. Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, Porcella S, Wang H, Herrmann E, McHutchison J, Suffredini AF, Polis M, Hewitt S, Prokunina-Olsson L, Masur H, Fauci AS, Kottilil S. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest. 2014 Aug; 124(8):3352-63. PMID: 24983321.
      View in: PubMed
    33. Meissner EG, Nelson A, Marti M, Masur H, Osinusi A, Kottilil S. Sustained Virologic Response for Chronic Hepatitis C Infection after 27 Days of Treatment with Sofosbuvir and Ribavirin. Open Forum Infect Dis. 2014; 1(1):013. PMID: 25411655.
      View in: PubMed
    34. Meissner EG, Bon D, Prokunina-Olsson L, Tang W, Masur H, O'Brien TR, Herrmann E, Kottilil S, Osinusi A. IFNL4-?G genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis. 2014 Jun 01; 209(11):1700-4. PMID: 24367041.
      View in: PubMed
    35. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, Sneller M, Kohli A, Barrett L, Proschan M, Herrmann E, Shivakumar B, Gu W, Kwan R, Teferi G, Talwani R, Silk R, Kotb C, Wroblewski S, Fishbein D, Dewar R, Highbarger H, Zhang X, Kleiner D, Wood BJ, Chavez J, Symonds WT, Subramanian M, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013 Aug 28; 310(8):804-11. PMID: 23982366.
      View in: PubMed
    36. Meissner EG, Suffredini AF, Kottilil S. Opportunities in proteomics to understand hepatitis C and HIV coinfection. Future Virol. 2012 Aug; 7(8):759-765. PMID: 23105947.
      View in: PubMed
    37. Meissner EG, Bennett JE, Qvarnstrom Y, da Silva A, Chu EY, Tsokos M, Gea-Banacloche J. Disseminated microsporidiosis in an immunosuppressed patient. Emerg Infect Dis. 2012 Jul; 18(7):1155-8. PMID: 22709509.
      View in: PubMed
    38. Zhang L, Meissner E, Chen J, Su L. Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis. Sci China Life Sci. 2010 Feb; 53(2):195-203. PMID: 20596827.
      View in: PubMed
    39. Sivaraman V, Zhang L, Meissner EG, Jeffrey JL, Su L. The heptad repeat 2 domain is a major determinant for enhanced human immunodeficiency virus type 1 (HIV-1) fusion and pathogenicity of a highly pathogenic HIV-1 Env. J Virol. 2009 Nov; 83(22):11715-25. PMID: 19726524.
      View in: PubMed
    40. Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog. 2007 Aug 24; 3(8):e117. PMID: 17722977.
      View in: PubMed
    41. Meissner EG, Zhang L, Jiang S, Su L. Fusion-induced apoptosis contributes to thymocyte depletion by a pathogenic human immunodeficiency virus type 1 envelope in the human thymus. J Virol. 2006 Nov; 80(22):11019-30. PMID: 16956934.
      View in: PubMed
    42. Meissner EG, Coffield VM, Su L. Thymic pathogenicity of an HIV-1 envelope is associated with increased CXCR4 binding efficiency and V5-gp41-dependent activity, but not V1/V2-associated CD4 binding efficiency and viral entry. Virology. 2005 Jun 05; 336(2):184-97. PMID: 15892960.
      View in: PubMed
    43. Meissner EG, Duus KM, Gao F, Yu XF, Su L. Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope. Virology. 2004 Oct 10; 328(1):74-88. PMID: 15380360.
      View in: PubMed
    44. Meissner EG, Duus KM, Loomis R, D'Agostin R, Su L. HIV-1 replication and pathogenesis in the human thymus. Curr HIV Res. 2003 Jul; 1(3):275-85. PMID: 15046252.
      View in: PubMed
    45. Aprelikova ON, Fang BS, Meissner EG, Cotter S, Campbell M, Kuthiala A, Bessho M, Jensen RA, Liu ET. BRCA1-associated growth arrest is RB-dependent. Proc Natl Acad Sci U S A. 1999 Oct 12; 96(21):11866-71. PMID: 10518542.
      View in: PubMed
    Meissner's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (226) concept(s)
    _
    Co-Authors Expand Description
    See all (14) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department